Investigators to Share New Data from Four Late-Breaking Clinical Trials


A high-profile Clinical Trials Symposium will feature new breakthroughs in the treatment and management of pulmonary disorders in adults and children. Breaking News: Clinical Trial Results in Pulmonary Medicine will take place on Monday, May 22, from 9–11 a.m. ET in Ballroom C (Level 3) of the Walter E. Washington Convention Center. 

The leaders of four phase two and phase three trials will present the results of their research for the first time in a public forum. The novel findings will provide important new understanding related to the use of inhaled therapy for pulmonary hypertension, a novel small molecule that controls chronic obstructive pulmonary disease symptoms and exacerbation, potential for unique dual-target biologic therapy for asthma, and a breakthrough related to the use of an asthma biologic in the treatment of COPD.

Robert P. Frantz, MD, director of the Pulmonary Hypertension Clinic and professor of medicine, Mayo Clinic, will review results from TORREY, which evaluated the efficacy and safety of inhaled seralutinib in adults with pulmonary arterial hypertension in a phase two randomized, double-blind, placebo-controlled trial.

Antonio Anzueto, MD, ATSF, professor of medicine and pulmonary section chief of Pulmonary, South Texas Veterans Healthcare System, will present results from the ENHANCE trials on the effectiveness of ensifentrine, which combines bronchodilator and non-steroidal anti-inflammatory therapy in a single compound, for the treatment of COPD.

Benjamin T. Suratt, MD, clinical lead for early development, immunity and inflammation for Sanofi, will discuss how dual targeting of thymic stromal lymphopoietin and interleukin 13 by the NANOBODY Molecule SAR443765 can reduce fractional exhaled nitric oxide in asthma following a single dose administered by subcutaneous injection.

Klaus F. Rabe, MD, PhD, professor, LungenClinic Grosshansdorf, Germany, will discuss the efficacy and safety of dupilumab in COPD with type 2 inflammation.

Don’t Miss On-Demand Highlights

Unable to attend every session of interest at the ATS 2023 International Conference? Or couldn’t join us in Washington, DC? Access some of the conference’s best content through the ATS 2023 On-Demand Highlights platform, available this summer. It will include more than 100 scientific and clinical symposia, including Keynote sessions, Clinical Year in Review, and Adult and Pediatric Core Curriculum.